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Abstract  
 
Recent evidence underlines the crucial role of neuronal cytoskeleton in the pathophysiology 
of psychiatric diseases. In this line, the deletion of STOP/MAP6 (Stable Tubule Only 
Polypeptide), a microtubule-stabilizing protein, triggers various neurotransmission and 
behavioral defects, suggesting that STOP knockout (KO) mice could be a relevant 
experimental model for schizoaffective symptoms. To establish the predictive validity of such 
a mouse line, in which the brain serotonergic tone is dramatically imbalanced, the effects of a 
chronic fluoxetine treatment on the mood status of STOP KO mice were characterized. 
Moreover, we determined the impact on mood of a chronic treatment by epothilone D, a 
taxol-like microtubule-stabilizing compound that has previously been shown to improve the 
synaptic plasticity deficits of STOP KO mice. We demonstrated that chronic fluoxetine was 
either anti-depressive and anxiolytic, or pro-depressive and anxiogenic, depending on the 
paradigm used to test treated-mutant mice. Furthermore, control-treated STOP KO mice 
exhibited paradoxical behaviors, compared to their clear-cut basal mood-status. Paradoxical 
fluoxetine effects and control-treated STOP KO behaviors could be due to their hyper-
reactivity to acute and chronic stress. Interestingly, both epothilone D and fluoxetine chronic 
treatments improved the short-term memory of STOP KO mice. Such treatments did not 
affect the serotonin and norepinephrine transporter densities in cerebral areas of mice. 
Altogether, these data demonstrated that STOP KO mice could represent a useful model to 
study the relationship between cytoskeleton, mood and stress. and to test innovative mood 
treatments, as microtubule-stabilizing compounds. 
 
 
 
Keywords: antidepressant, anxiety/depression, corticosterone, microtubule-stabilizing 
compound, serotonin/norepinephrine transporters, stress. 
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Introduction 
 
Schizophrenia and mood disorders are common, chronic and debilitating psychiatric 
illnesses, which have a high prevalence, regardless of countries and cultures, and have a 
considerable socio-economic cost (Eaton et al. 2008). For example, unipolar major 
depression, bipolar disorder and schizophrenia are ranked 1st, 6th and 9th, respectively, in 
the World Health Organization estimates for disease-related lifetime disabilities and 2% of 
humans are affected by schizophrenia or bipolar disorder (Lopez et al. 2006, Mathers & 
Loncar 2006). Although, the aetiology of schizophrenia and mood disorders is yet poorly 
understood, converging evidences support the view that they can arise from a deficit in 
cerebral connectivity, synaptic plasticity and/or neuronal architecture (Mirnics et al. 2001, 
Frankle et al. 2003, Owen et al. 2005, Schloesser et al. 2008).  
Microtubules and microtubule effectors are of fundamental importance to neuronal 
differentiation and functions. Dysfunctions of the microtubule network have been shown to 
lead to neurodegenerative diseases and to psychiatric disorders (Gardiner et al. 2011). 
Recently, it was found that microtubule deregulation and alterations were related to 
modifications of integrated brain functions both in animal models and in psychiatric diseases. 
The first evidence for such a role of cytoskeleton disorganization in psychiatric-like 
characteristics arises from the deletion in mice of the microtubule-stabilizing protein STOP 
(Stable Tubule Only Polypeptide, Andrieux et al. 2002). Indeed, STOP knockout (KO) mice 
exhibit abnormalities of glutamatergic, dopaminergic, acetylcholinergic/nicotinic, serotonergic 
and noradrenergic neurotransmissions, deficits of neuronal and synaptic plasticity, 
sensorimotor gating impairment, associated with profound and widespread behavioral 
defects (Andrieux et al. 2002, Brun et al. 2005, Fradley et al. 2005, Bouvrais-Veret et al. 
2007 and 2008, Powell et al. 2007, Delotterie et al. 2010, Kajitani et al. 2010, Fournet et al. 
2010, 2012). The overall phenotype of STOP KO mice suggests that they represent a 
relevant experimental model for schizoaffective-like characteristics. Other studies, based on 
human genetics, also indicate relationship between microtubule regulatory proteins and 
mental functions. For example, dysbindin-1 gene mutations have been reported in both 
schizophrenic (Straub et al. 2002, Benson et al. 2004, Norton et al. 2006) and bipolar 
patients (Maier 2008, Domschke et al. 2011) and this protein interacts with and regulates 
microtubules (Talbot et al. 2006). Similarly, mutations in DISC1 (Disrupted-In-Schizophrenia 
1) gene are associated with several psychiatric diseases (schizophrenia, bipolar disorders, 
depression and autism (Millar et al. 2000, Ishizuka et al. 2006, Blackwood et al. 2007, Chubb 
et al. 2008, Kilpinen et al. 2008) and its product is a multifunctional protein acting on 
microtubules and on microtubule-regulatory proteins (Morris et al. 2003, Kamiya et al. 2006, 
Taya et al. 2007).  
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A large portion of psychiatric patients are refractory to therapeutic drugs and, during 
drug treatments, some symptoms are moderately improved or resistant to the current 
therapy. For example, antipsychotics do not improve negative symptoms and cognitive 
deficits (Keefe et al. 2007), in spite of a therapeutic benefit for positive schizophrenia 
symptoms (Seeman et al. 2006). In addition, some drugs need a delay for their therapeutic 
action, as in the case of antidepressants that necessitate 3-6 weeks to be active (Blier & de 
Montigny 1994). Finally, most of psychiatric drugs elicit a broad range of undesirable side 
effects, which often lead patients to cease their treatment. Based on such evidence, there is 
the need to find innovative targets and develop novel therapeutic drugs. In addition, an 
essential prerequisite for the suitability of an experimental rodent line to model psychiatric-
like symptoms is that some deficits will be improved by current therapy (pharmacological or 
predictive validity). 
In the case of STOP KO mice, chronic treatments by both typical and atypical 
antipsychotics improve some defects, such as the reduced number of hippocampal synaptic 
vesicles, the post-tetanic potentiation and/or the long-term potentiation (PTP and LTP, 
respectively) deficits, the nursing behavior of STOP KO females, the locomotor hyperactivity, 
the fragmenteous activity and the social interaction (Andrieux et al. 2002, Brun et al. 2005, 
Fradley et al. 2005, Delotterie et al. 2010, Merenlender-Wagner et al. 2010). Interestingly, a 
chronic treatment by epothilone D, a taxol microtubule-stabilizing compound (Kolman 2004, 
Nettles et al. 2004), also improved some deficits of STOP KO mice. In fact, it reduces the 
decrease of the hippocampal synaptic number, improves PTP and LTP and alleviates their 
disorganized spontaneous activity and maternal care deficit (Andrieux et al. 2006). 
We recently show that the deletion of the STOP protein triggers a high imbalance of 
serotonin (5-HT) neurotransmission, with dramatic consequences (Fournet et al. 2010, 
2012). Indeed, STOP KO mice are highly depressed and very less anxious than their WT 
littermates and exhibit impaired short- and long-term memories and spatial learning. 
Therefore, we characterized the effects of chronic treatment by fluoxetine, a widely used 
antidepressant selective for 5-HT reuptake, as well as of chronic treatment by epothilone D. 
Both chronic treatments were tested on mood-status and cognitive memory of wild-type (WT) 
and STOP KO mice. Moreover, due to paradoxical responses of chronic control-treated 
STOP KO mice in some behavioral tasks, we tested their reactivity toward an acute stress. 
Finally, we measured the effects of fluoxetine and epothilone D chronic treatments on the 
density of serotonin (SERT) and norepinephrine (NET) transporters, in brain areas of mice of 
both genotypes.  
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Materials and Methods 
 
Animals 
Homozygous WT and STOP KO mice were obtained by crossing heterozygous C57BL6 
STOP with heterozygous 129 SvPas STOP to get inbred C57BL6 x 129 SvPas-F1 mice and 
were genotyped as previously described (Andrieux et al. 2002). All mice were kept under 
standard conditions, under a 12 h light/dark cycle (lights on at 07h30) and allowed to 
habituate to the animal holding room for at least one week prior to use. All experiments were 
conducted on WT and STOP KO males of the same litters, at 3-5 months of age, in 
accordance with the European Communities Council directive (86/809/EEC). 
 
Drugs and treatments 
Desipramine hydrochloride was purchased from Tocris (Bristol, UK), fluoxetine hydrochloride 
from Sigma-Aldrich (Saint Quentin-Fallavier, France) or Lilly France (Prozac®, Suresnes, 
France) and epothilone D from GBF (Braunschweig, Germany). [3H]Citalopram (2.22-3.18 
TBq/mmol) and [3H]nisoxetine (2.22-3.18 TBq/mmol) were from Perkin Elmer (Orsay, 
France). [125I]-RIA kit for corticosterone dosages was purchased from MP Biomedicals 
(Orangeburg, USA).  
Epothilone D was diluted in warm water from a 16.67 mg/ml stock solution in dimethyl 
sulfoxide. Fluoxetine (Prozac®, 280 mg/70 ml) was diluted in tap water. Male mice were 
housed five per cage, two cages (10 mice) per treatment and per genotype. Six groups of 
male mice were constituted: control-treated WT and STOP KO mice received, from day 0 
and once a week, a peritoneal administration of 0.6% dimethyl sulfoxide (100 µl/10 g body 
weight) and, from day 7, 12 mg/ml saccharose plus 3.2 µl/ml glycerol in their tap drinking 
water; epothilone-treated WT and STOP KO mice received, from day 0 and once a week, a 
peritoneal administration of 1 mg/kg epothilone D (100 µl/10 g body weight) and, from day 7, 
12 mg/ml saccharose plus 3.2 µl/ml glycerol in their tap drinking ater; fluoxetine-treated WT 
and STOP KO mice received, from day 0 and once a week, a peritoneal administration of 
0.6% dimethyl sulfoxide and, from day 7, 0.05-0.07 mg/ml fluoxetine in their tap drinking 
water. To adjust the fluoxetine dosage at about 10 mg/kg/day/mouse, the liquid consumption 
and the body weight were regularly monitored. Behavioral tests were conducted after at least 
6 weeks for epothilone D treatment and 5 weeks for fluoxetine treatment (supplementary 
data, Fig. S1A). Chronic epothilone D and fluoxetine treatments were pursued during all the 
behavioral studies, but were washed out one week before sacrifices.  
To study the sensitivity of mice towards acute stress, animals received physiological 
serum (100 µl/10 g body weight, i.p.) or not (basal) and were tested 30 min later in some 
tasks. 
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Behavioral tests 
All experiments were conducted between 10h00 and 16h00, in a sound attenuated test room 
where mice were allowed to habituate at least 30 min before the task. 
 
Coat State 
The coat state of treated mice was evaluated periodically by a well-trained experimenter 
blind to genotypes and treatments. Assessment of the coat state took into account the whole 
body, i.e. fur clogging, cleanness, density and scars, according to Farley et al. (2012). A 
score was attributed to each mouse on a scale from 0 (dirty coat) to 20 (bright and clean 
coat). 
 
Splash Test 
The splash test, adapted from Yalcin et al. (2008), consisted of squirting a 10% sucrose 
solution on the dorsal coat of a mouse in its home cage, under 15 lux illumination. After 
applying sucrose solution, the latency before the first grooming episode and time spent 
grooming were recorded for 5 minutes. The score of 1 epothilone-treated KO mouse, which 
did not groom, was not taken into account in analysis. 
 
Forced Swimming Test 
The forced swimming test was adapted from Porsolt et al. (1979, supplementary data). 
Latency before the first episode of immobility, the total duration of immobility and the number 
of climbing attempts were recorded for 6 min. The scores of 1 control- and 1 epothilone-
treated STOP KO mice, which did not exhibit immobility episode, were not taken into account 
in analysis. 
 
Tail Suspension Test 
Mice were suspended by the tail, using a paper adhesive tape, to a hook in a chamber of the 
apparatus (Bioseb, Vitrolles, France) under a 15 lux illumination. Their immobility time was 
automatically recorded during 6 min. 
  
Marble Burying Test 
The marble burying test was adapted from Millan et al. (2001, supplementary data). The 
number of marbles buried by each mouse was scored every minute for 10 min and then 
every 5 min up to 20 min. 
 
Light/Dark Box Test 
The apparatus consisted of a box (50 x 30 x 30 cm) divided by an open door providing 
access to a white illuminated open area (300 lux) and a dark black enclosed area (5 lux). 
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Mice were placed in the center of the dark area and latency to enter in the bright area, the 
number of visits (with four paws) and the total time spent in the bright area were measured 
for 9 minutes. 
 
Spontaneous Alternation 
This test was performed under 5 lux illumination in a Y-maze (supplementary data). The 
number and the sequence of visits into the 3 arms were recorded during 5 min. The score of 
1 fluoxetine-treated WT mouse, which stayed immobile during the 5 min-test, was not taken 
into account in analysis. 
 
Novel Object Recognition Task 
This test was conducted in an arena under a 50 lux illumination (supplementary data). After 
habituation to arena and to objects, each mouse was placed in the center of the arena for 8 
min in the presence of four identical new objects (sample phase). Mice were then removed 
and, after 10 min, returned to the arena during 8 min for the choice phase, with two objects 
from the sample phase (familiar objects) and two novel identical objects. The times spent to 
explore novel and familiar objects were recorded. Scores of one control-treated WT, one 
fluoxetine-treated WT and one fluoxetine-treated STOP KO mouse, which did not explore 
objects, were not taken into account in analysis. 
 
Autoradiographic labelings of 5-HT and NE transporters  
Labelings of SERT and NET were performed, as detailed in supplementary data, after a 7-
days washout of chronic treatments to avoid occupancy of the monoamine transporters by 
fluoxetine, 5-HT and/or NE. 
 
Plasma corticosterone measurements 
Naïve mice received or not an intraperitoneal administration of physiological serum (100 
µl/10 g body weight) and were killed by cervical dislocation 30 min later. Their plasma was 
immediately harvested and plasma corticosterone level was determined by 
radioimmunoassay according to the kit manufacturer’s instructions.  
 
Statistical analyses 
Data were subjected to factorial one-, two-, three- or four-way ANOVA, with genotype, 
treatment, area or object as between-group factors and time as within-group factor. 
Significant main effects were further analyzed by post hoc comparisons of means using 
Fisher's or Student‘s t test. The parameters of linear regressions were calculated using 
GraphPad prism 5.0 software. For all tests, statistical significance was set at p < 0.05. 
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Results 
 
The dose of the duration of chronic treatments by epothilone D and fluoxetine were selected 
according to previous studies (Fournet et al. 2012, supplementary data). We have chosen to 
characterize the effects of chronic epothilone D and fluoxetine treatments on three 
depression and two anxiety tests, as well as on two memory performance tasks, based on 
the clear-cut basal phenotype of STOP KO mice (Fournet et al. 2012). Moreover, all mice 
underwent the same series of tests to avoid different stress and environmental effects 
(supplementary data, Fig. S1A). 
 
Fluoxetine intake during chronic treatments (Fig. S2) 
All along the chronic treatments by epothilone D or fluoxetine, the body weight and the fluid 
consumption of mice were monitored (Figs. S1B and S2, supplementary data). During the 
test period (41-63 days), the intake of fluoxetine was similar between WT and STOP KO 
mice (10.6 ± 0.6 and 10.8 ± 0.6 mg/kg/day, respective mean dose, Fig. S2B). 
 
Effect of chronic treatments on the depression-status  
Coat state (Fig. 1A) 
The coat state of treated-WT and -STOP KO males was regularly assessed during the 
chronic treatments by the same experimenter. Statistical analyses showed significant effects 
of genotype, treatment and time (Table S1).  
 As already reported (Fournet et al. 2012), the coat state of male STOP KO mice was 
worse than that of WT mice, whatever the treatment (control: -29%, p = 0.0002; epothilone 
D: -21%, p = 0.0056; fluoxetine: -39%, p < 0.0001, repeated measures). The coat state of 
control-treated WT mice was aggravated between days 7 and 58 (-46%, p = 0.0018), 
whereas that of control-treated STOP KO mice remained constant. Accordingly, at day 58, 
the coat state of control-treated WT and STOP KO mice was no longer different.  
Epothilone D treatment had no effect on the coat state of both WT and mutant mice. 
In contrast, chronic fluoxetine significantly improved the coat state of males of both 
genotypes (WT: +48%, p < 0.0001; STOP KO: +28%, p = 0.0091; repeated measures; WT: 
+137%, p < 0.0001, KO: +47%, ns; between days 7 and 58). These latter data indicated that 
chronic fluoxetine was more efficacious to improve the coat state of treated-WT than -STOP 
KO mice. 
 
Splash test (Fig. 1B) 
Statistical analysis indicated significant effects of genotype and a near significant effect of 
treatment on latency to groom and of genotype and treatment on the grooming duration 
(Table S1). 
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 As already reported (Fournet et al. 2012), control treated-STOP KO mice displayed 
an increased careless behavior compared to control-treated mice, characterized by an 
increased latency to groom (+144%, p = 0.0003) and a decreased grooming (-42%, p = 
0.0038). 
Epothilone D treatments had no effect on the grooming of WT and STOP KO mice. 
However, fluoxetine treatment exerted an antidepressant-like effect on treated-STOP KO 
mice by decreasing the latency (-37%, p = 0.0179) and increasing the grooming (+54%, p = 
0.0038), while it had no effect on WT performances. Finally, the grooming performances of 
fluoxetine-treated STOP KO mice did no longer differ from that of control-treated WT mice. 
The significant improvement by fluoxetine treatment of the grooming behavior (state 
coat and splash test) of STOP KO mice was in agreement with previous study on 
unpredictable chronic mild stressed mice (Mutlu et al. 2009).  
 
Forced swimming test (Fig. 1C) 
This test was preferred to the tail suspension test since the determination of climbing 
attempts also provides information about the norepinephrine tonus of treated-mice. Statistical 
analyses showed significant effects of genotype and treatment on the latency, of genotype, 
treatment and time on the immobility, and of genotype and time on the climbing (Table S1). 
In contrast with previous study performed in basal conditions (Fournet et al. 2012), 
the performances of control-treated STOP KO indicated a lesser despair behavior compared 
to WT mice, exhibiting a decreased immobility (-62%, p < 0.0001, repeated measures) and 
increased climbing attempts (+135%, p = 0.0085, repeated measures). On the other hand 
and as already reported (Fournet et al. 2012), latency before the first immobility episode of 
STOP KO mice was lesser than WT mice (-71%, p = 0.0014).   
 Chronic epothilone D and fluoxetine treatments induced helplessness in mice of both 
genotypes, by decreasing latency of treated-WT mice (epothilone: -73%, p = 0.0007; 
fluoxetine: -78%, p = 0.0003) and increasing immobility (epothilone-WT: +67%, p < 0.0001; 
epothilone-KO: +123%, p = 0.0030; fluoxetine-WT: +34%, p = 0.0227; fluoxetine-KO: +400%, 
p < 0.0001). Epothilone D and fluoxetine had no effect on the number of climbing attempts of 
mice of both genotypes. 
 
Summary 
As in basal conditions (Fournet et al. 2012), control-treated STOP KO mice were more 
depressed than control-treated WT mice in the coat state assessment (up to day 58) and in 
the splash test. In contrast, control-treated mutant mice exhibited a less helplessness in the 
forced swimming test, in disagreement with previously reported basal behaviors (Fournet et 
al. 2012). Whereas epothilone D had no effect on the depression-status of WT and mutant 
mice measured by the coat state and by the splash test, it worsened performance of mice of 
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both genotypes in the forced swimming test. Fluoxetine chronic treatment had an 
antidepressant effect on WT and STOP KO mice in the coat state and on STOP KO mice in 
the splash test. In contrast, it exhibited a paradoxically pro-depressant effect on WT and 
STOP KO mice in the forced swimming test.  
 
Effect of chronic treatments on the anxiety-status  
Marble burying test (Fig. 2A) 
Genotype, treatment and time significantly affected the number of buried marbles (Table S1). 
 As already reported (Fournet et al. 2012), treated-STOP KO mice did not consider 
marbles as anxiogenic objects, since they buried less marbles than treated-WT mice (control: 
-33%, p = 0.0006; epothilone: -38%, p < 0.0001, fluoxetine: -100%, ns; repeated measures). 
Moreover, whereas epothilone D treatment had no effect on the anxiety-status of mice, 
fluoxetine treatment induced a significant anxiolytic effect on mice of both genotypes by 
decreasing the number of buried marbles (WT: -85%, p < 0.0001; STOP KO: -100%, p < 
0.0001, repeated measures). 
 
Light/dark box test (Fig. 2B) 
Statistical analyses indicated significant effects of treatment on the latency before the first 
visit in the light box, of treatment on the time spent in the light box, of genotype and 
treatment on the visits in the light box (Table S1). 
 In contrast with previous results (Fournet et al. 2012), control-treated STOP KO mice 
did not exhibit a reduced anxiety in this test compared to control-treated WT. Epothilone had 
no effect on the performance of treated-WT mice, while it elicited a slight anxiogenic effect on 
treated-STOP KO mice by decreasing their time spent into the light box (-43%, p = 0.0201). 
Fluoxetine treatment clearly exhibited an anxiogenic effect on both genotypes, increasing 
latency (WT: +216%, p = 0.0020; KO: +158%, p = 0.0629), d creasing the time spent (WT: -
89%, p = 0.0012; STOP KO: -77%, p < 0.0001) and the visits (WT: -79%, p = 0.0059; KO: -
66%, p = 0.0008) into the light box. 
 
Summary 
Control-treated STOP KO mice were less anxious than control-treated WT mice in the 
marble burying test, as already reported (Fournet et al. 2012). But, in disagreement with their 
previously reported basal performances, the anxiety-like status of control-treated STOP KO 
mice was not different from that of control-treated WT mice in the light/dark box test. 
Whereas epothilone D had little or no effect on the anxious-status of WT and mutant mice, 
fluoxetine elicited on both mouse lines an anxiolytic effect in the marble burying test, but an 
anxiogenic effect in the light/dark box test.  
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Chronic treatments improved the short-term memory of STOP KO mice  
Spontaneous alternation (Fig. 3A)  
Statistical analyses indicated a significant effect of genotype (but not of treatment) on the 
total visits in the three arms of the Y maze and no effect of genotype and treatment on the % 
spontaneous alternation (Table S1). 
 As in basal conditions (Fournet et al. 2012), the total number of visits in the 3 arms of 
treated-STOP KO compared to treated-WT mice was significantly increased (control: +45%, 
p = 0.0252; epothilone: +71%, p = 0.0007; fluoxetine: +126%, p = 0.0001), but the 
spontaneous alternation was not different between genotypes. Moreover, chronic epothilone 
and fluoxetine treatments had not effect on the two parameters. 
 
Novel object recognition (Fig. 3B)  
Statistical analyses showed significant effects of genotype and treatment on the total object 
recognition time (novel + familiar) during both the sample (not shown) and the choice tests 
and significant effects of object, of genotype x object and treatment x object interactions on 
the % time spent with novel and familiar objects (Table S1). 
 As previously reported (Fournet et al. 2012), the total exploratory time of treated-
STOP KO compared to treated-WT mice was increased (control: +138%, p < 0.0001; 
epothilone: +100%, p = 0.0058; fluox tine: +97%, p = 0.0249). Epothilone and fluoxetine 
treatments had no effect on the exploratory time of WT mice, while they decreased the 
exploratory time of STOP KO mice (epothilone: -23%, p = 0.0537; fluoxetine: -42%, p = 
0.0011). 
 In agreement with basal performances (Fournet et al. 2012), control-treated WT mice 
prefered novel objects after a 10-min interval between the sample- and choice-phases (p = 
0.0050), whereas control-treated STOP KO mice did not. Interestingly, both epothilone D and 
fluoxetine treatments improved the performances of STOP KO mice to distinguish the novel 
objects (%Novel different from %Familiar, epothilone: p = 0.0004; fluoxetine: p = 0.0004).  
 
Summary 
Whereas the control-treated STOP KO mice performed as well as control treated-WT mice in 
the spontaneous alternation test, they failed to distinguish between familiar and novel objects 
after a 10-min interval, as already reported (Fournet et al. 2012). Epothilone D and fluoxetine 
treatments had no effect on the spontaneous alternation of mice of both genotypes, however 
they improved the short-term memory of STOP KO mice and decreased their exploratory 
activity. 
 
 
 
Page 11 of 50 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
STOP KO mice were hyper-reactive to acute stress (Figs. 4 and 5) 
The paradoxical behaviors of control-treated STOP KO mice in the forced swimming and 
light/dark box tests, compared to their performances previously reported in basal conditions 
(Fournet et al. 2012), prompted us to analyze the effects of acute stress. Naïve male mice 
received or not an intraperitoneal administration of physiological serum and their depression- 
and anxious-performances were characterized 30 min later.  
 
Forced swimming test (Fig. 4A) 
Statistical analyses showed significant effects of genotype and stress on latency, of 
genotype, stress and time on the immobility time and on the climbing attempts (Table S2). 
 According to previous study (Fournet et al. 2012), non-injected STOP KO mice 
displayed a despair-like behavior compared to WT mice, characterized by decreased latency 
(-56%, p < 0.0001), more immobility (+29%, p = 0.0042, repeated measures) and less 
climbing attempts (-77%, p < 0.0001, repeated measures). 
 Whereas the saline injection had no effect on the overall behavior of WT mice, it 
affected significantly the behavior of STOP KO mice, which became less depressed. Indeed, 
saline administration decreased immobility (-46%, p < 0.0001, repeated measures), 
increased climbing attempts (+362%, p < 0.0001, repeated measures), but was without effect 
on latency.  
 
Tail suspension test (Fig. 4B) 
Genotype and stress had significant effects on the immobility time (Table S2). As already 
reported (Fournet et al. 2012), non-injected STOP KO mice displayed a depression-like 
behavior, being more immobile than WT mice (+59%, p = 0.0024). Whereas the acute stress 
had no effect on the immobility of WT mice, it reversed the depression-status of STOP KO 
mice, by decreasing the immobility of mutant males (-60%, p < 0.0001), so that it became 
significantly shorter than the one of saline-treated WT mice (-40%, p = 0.0295). 
 
Light/dark box test (Fig. 4C) 
Statistical analyses indicated significant effects of the genotype x stress interaction on 
latency, of genotype and stress on the time spent and the visits in the light box (Table S2). 
 According to previous study (Fournet et al. 2012), non-injected STOP KO mice 
displayed a less anxious-like behavior than WT mice, with decreased latency before the first 
entry in the light box (-59%, p = 0.0067), increased time spent (+99%, p < 0.0001) and visits 
(+142%, p < 0.0001) into the light box. The acute stress had no effect on the behavior of WT 
mice, while it had an anxiogenic effect on STOP KO mice, by increasing latency (+117%, p = 
0.0314) and decreasing both time and visits (time: -52%, p < 0.0001; visits: -50%, p < 
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0.0001). Finally, the performances of saline-treated mutant mice were no longer different 
from that of WT mice.  
 
Plasma corticosterone levels (Fig. 5) 
Accordingly, we measured the plasma corticosterone in basal conditions or 30 min after 
saline administration to naïve WT and STOP KO males. Genotype and stress had significant 
effects on the corticosterone level (Table S2). 
 In basal conditions, the plasma corticosterone level of STOP KO mice was higher 
(+83%, p = 0.0003), than that of WT mice. Saline administration induced, 30 min later, a 
significant increase of plasma corticosterone levels in mice of both genotypes (WT: +159%, p 
< 0.0001; KO: +59%, p < 0.0001) and the corticosterone level was no longer different 
between saline-treated WT and mutant mice. Accordingly, the % stress-induced 
corticosterone increase was significantly lower in saline-treated STOP KO than in WT mice 
(p < 0.0001). 
 
Summary 
The acute stress of STOP KO mice elicited an antidepressant-like effect in the forced 
swimming and the tail suspension test and an anxiogenic-like effect in the light/dark box test, 
whereas it had no effect on WT mouse performances. These results showed that acutely 
stressed-STOP KO mice behaved in the same manner than chronic control-treated mutants 
in these tests. Moreover, based on their plasma corticosterone level, STOP KO mice were 
more stressed than WT mice in basal conditions, but were hyporeactive to saline 
administration stress. 
 
Chronic treatments had no effect on SERT and NET densities (Fig. 5B, Tables S3-S4)  
To tentatively explain the effects of chronic treatments, we measured the density of SERT 
and NET in various brain areas of treated-WT and -STOP KO mice. Genotype and area (but 
not treatment) had significant effects on the SERT and NET densities (Table S1). 
As already reported (Fournet et al. 2012), parallel marked variations of SERT (Table 
S3) and NET (Table S4) densities were noted in control-treated STOP KO mice, with 
increases in the monoaminergic somas and decreases in all the projections areas. 
Interestingly, epothilone D and fluoxetine chronic treatments had no effect in the density of 
SERT and NET in all tested areas in mice of both genotypes, suggesting that the behavioral 
effects of chronic epothilone D and fluoxetine treatments are not mediated by changes in 
SERT and NET densities.  
The variations of SERT and NET densities in STOP KO mice, expressed as % of 
respective WT values, were highly correlated in basal conditions (Fournet et al. 2012) and 
after control-treatment (Fig. 5B; SERT: F(1,20) = 669.0, p < 0.0001; NET: F(1,24) = 268.0, p 
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< 0.0001). But, whereas the slope of the linear regression for NET was not different from 1, 
the slope for SERT correlation was significantly higher than 1 (1.170 ± 0.045, p < 0.001). 
This result indicated that the chronic stress, induced by weekly drug administrations and 
numerous handlings, aggravated the disequilibrium of the 5-HT network of STOP KO mice 
by 17%, while it was inactive on the NE tone 
 
Compared effects of acute and chronic stress and of chronic fluoxetine on the mood 
of WT and STOP KO males (Tables 1-S5) 
The performances of STOP KO versus WT males in depressed-like and anxiety-like 
paradigms were compared in basal conditions, as already reported (Fournet et al. 2012), 
after acute stress due to saline administration and chronic stress due to vehicle (control)-
treatment (this study). The effects of chronic fluoxetine treatment were also compared on WT 
and STOP KO mood-status. Statistical analyses were depicted in Table S2. 
Acute stress had no effect on the WT male mood. In contrast, acute stress of STOP 
KO males reversed (improved) their depression-status in the forced swimming and tail 
suspension tests and reversed (aggravated) their anxiety-status in the light/dark box. 
Chronic stress worsened the coat state of WT males, which became equally 
depressed than STOP KO mice. It had no or variable (depending on the parameter) effect on 
the splash test and the forced swimming tests in WT males. It improved the anxiety-status of 
WT mice in the marble burying test, but had no effect on their performances in the light/dark 
box. Chronic stress elicited no effect on the coat state of STOP KO mice, an antidepressant 
effect on the splash test and the forced swimming test. It had no effect on the anxiety-status 
of STOP KO mice in the marble burying test, but rev rsed (aggravated) their performances in 
the light/dark box. 
Compared to chronic stress, chronic fluoxetine treatment improved the coat state of 
mice of both genotypes, with a higher effect on WT than on STOP KO males. It had no effect 
on WT mice in the splash test, a slightly aggravating effect on their performances in the 
forced swimming test, an anxiolytic effect on the marble burying test, but an anxiogenic effect 
on the performances of WT mice in the light/dark box test. Chronic fluoxetine improved the 
behavior of STOP KO mice in the splash test, but aggravated their depression-status in the 
forced swimming test. Moreover, chronic fluoxetine treatment improved the anxiety-status of 
STOP KO males in the marble burying test, but aggravated their performances in the 
light/dark box test. 
 
In summary, STOP KO males were hyper-reactive to acute stress and differentially 
sensitive to chronic stress in the different behavioral tests used. Furthermore, the two tests in 
which the performances of STOP KO males were inversed by acute and chronic stress, 
compared to basal conditions, were those in which chronic fluoxetine exerted a paradoxical 
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aggravating effect both in WT and STOP KO mice, i.e. pro-depressant in the forced 
swimming test and anxiogenic in the light/dark box test.  
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Discussion 
 
The effects on STOP KO mice of a chronic treatment with fluoxetine, a selective SERT 
inhibitor, could not be foreseeable, due to the dramatic decrease of SERT density in all brain 
projection areas of these mice (Fournet et al. 2010, 2012). However, our present study 
indicated that fluoxetine treatment exerted some effects on the mood of mutant mice. Indeed, 
chronic treatment by fluoxetine either improved or worsened the depression- and anxiety-
status of mutant mice. Control-treated STOP KO mice also exhibited paradoxical behaviors, 
compared to their basal status (Fournet et al. 2010). We hypothesized that the peculiar 
behavior of control-treated STOP KO mice, as well as the aggravating effects of chronic 
fluoxetine treatment, were triggered by an altered sensitivity of mutants to stress. Indeed, 
stress is believed to be a causal factor in the pathogenesis of psychiatric diseases, especially 
in mood disorders (McEwen 2003). Accordingly, we showed that acutely stressed STOP KO 
mice displayed a less depressed- and more anxious-status in some tests, in disagreement 
with their basal status. Mutant mice also exhibited enhanced plasma corticosterone level, but 
decreased stress-induced corticosterone stimulation. Worthy of note, our data demonstrated 
that both epothilone D and fluoxetine chronic treatments improved the short-term memory of 
STOP KO mice in the novel object recognition task. Finally, neither fluoxetine, nor epothilone 
D effects were due to variations of SERT and NET densities in the various brain areas 
tested.  
 
Paradoxical effects of fluoxetine on the mood-status of STOP KO mice  
We recently demonstrated that STOP KO mice exhibited high variations in SERT density, 
which increase in 5-HT somas and highly decrease in all the projection areas, triggering 
dramatic consequences on mood (Fournet et al. 2010, 2012). Actually, STOP KO mice 
displayed a clear-cut mood in basal conditions, i.e. a depr ssed- and less anxious-status. 
Our present data demonstrated that fluoxetine treatment triggered effects on the mood status 
of STOP KO mice, in spite of the highly disequilibrium of their 5-HT tone.  
However, whereas chronic fluoxetine treatment clearly improved the grooming 
behavior of STOP KO mice, tested by the coat state and the splash test, it elicited a 
paradoxical response of mutant mice in the forced swimming test, another standardized 
paradigm for the assessment of despair behavior. Indeed, chronic fluoxetine-treatment of 
STOP KO mice worsened their depressed-status, by increasing their immobility time and 
decreasing (although not significantly) their climbing attempts and latency. The same 
paradoxical effect of fluoxetine was also found in the forced swimming test after an acute 
treatment of STOP KO mice (Fournet and Martres, unpublished observations). In the same 
manner, chronic fluoxetine treatment elicited an anxiolytic effect on STOP KO mice in the 
marble burying test, but an anxiogenic effect in the light/dark box test, by decreasing the time 
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spent and number of visits in the light box of mutants. These paradoxical effects of chronic 
fluoxetine could unlikely be due to the fluoxetine dosage selected for chronic treatment. The 
relatively low dose of fluoxetine was chosen according to its acute effect on the tail 
suspension test (Fournet et al. 2012). At the dose of 10 mg/kg, fluoxetine had no effect on 
the immobility of WT mice, whereas it significantly decreased the immobility of STOP KO 
mice. Also, the aggravating effects of fluoxetine were not due to opposite effects on WT 
mice, since fluoxetine parallely affected mood of WT and STOP KO mice in these tests.  
Interestingly, the two tests upon which chronic fluoxetine exerted a paradoxical effect, 
i.e. pro-depressant in the forced swimming test and anxiogenic in the light/dark box test, 
were also those in which control-treated STOP KO mice responded in a paradoxical manner. 
 
Mutant mice were hyper-reactive to acute stress and not tolerant to chronic stress  
Although STOP KO mice clearly exhibited a highly depressed-status and decreased anxiety-
status on a series of different tests (Fournet et al. 2012), they exhibited paradoxical 
responses to some despai - and anxiety-tests after chronic treatment with vehicule (control-
treated). For example, they displayed a depressed-like behavior in the splash test, but they 
were less depressed than control-treated WT mice in the forced swimming test. In the same 
manner, whereas control-treated STOP KO were lesser anxious in the marble burying test 
than WT mice, they were equally anxious in the light/dark box test. However, such an 
inverted behavior of STOP KO mice was not due to changes in the mood status of control-
treated WT mice. Indeed, control-treatment of WT mice had variable effects in the forced 
swimming and no effect in the light/dark box. Accordingly, these opposite behaviors of 
mutant mice prompted us to test the effects of an acute stress on their mood.  
We showed that STOP KO mice were hyper-reactive to acute stress, contrasting with 
WT mice. In fact, an acute mild stress, induced by a peritoneal administration of saline 30 
min before testing, could reverse both the depressed and the less anxious phenotype of 
STOP KO mice in selected tests. Acute stress exerted an antidepressant effect in mutant 
mice in the forced swimming and in the tail suspension tests, compared to basal (non-
injected) conditions. In the same manner, acute stress had an anxiolytic effect on STOP KO 
mice in the light/dark box test. This hyper-reactivity of STOP KO mice to acute mild stress 
has already been reported on their locomotor activity (Brun et al. 2005, Fradley et al. 2005, 
Begou et al. 2007). In addition, our data suggested that STOP KO mice were not tolerant to 
chronic stress, since acute and chronic vehicule administration induced the same inverted 
effects on their mood (see Tables 1 and S5).  
The corticosterone plasma level in basal conditions was elevated in STOP KO mice 
compared to WT, indicating that mutant mice were more stressed than their WT littermates. 
However, 30 min after saline administration, the increase in corticosterone level, expressed 
as percent of respective basal levels, was significantly lower in STOP KO than in WT mice. 
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This suggests that the hypothalamic-pituitary-adrenal (HPA) axis in mutant mice may be 
desensitized, possibly as a consequence of a chronic state of stress. Moreover, the HPA axis 
being excitated by both noradrenergic and serotonergic neurotransmissions (Herman et al. 
2003, Lanfumey et al. 2008), the decreased levels of 5-HT and NE found in projection areas 
of STOP KO (Fournet et al. 2012) could under-regulate the HPA axis.  
Such a desensitization of the HPA axis in mutant mice was in disagreement with their 
behavioral hyper-reactivity to acute and chronic stress. An explanation of this discordance 
will be that the tests chosen to characterize the effect of stress, i.e. the forced swimming, tail 
suspension and light/dark box tests, triggered a significantly higher additional stress and that 
the HPA axis in mutant mice, whereas desensitized to mild stress, was hyper-reactive to 
higher stress. Another explanation will be that the stress induced by these behavioral tests 
will imply different molecular pathways from those dependent of the HPA axis.  
The parallelism between the paradoxical effects of fluoxetine and the paradoxical 
behaviors of control-treated STOP KO mice suggested that both chronic fluoxetine treatment 
and chronic stress acted by the same molecular mechanism(s). Finally, since only some 
tests were sensitive to stress, whereas other did not, it appears to be necessary to use a 
battery of tests to characterize the depression- and anxiety-status of mutant mice as STOP 
KO mice, in order to avoid stress artifacts. 
 
Chronic epothilone D had little if any effect on the mood of STOP KO mice 
The chronic treatment by epothilone D, a microtubule-stabilizing taxol analog, -used in 
cancerology, which can cross the blood-brain barrier- only marginally affected the mood of 
STOP KO mice and had no effect on the mood of WT mice. It acted as a pro-depressant on 
the immobility time of mutant mice in the forced swimming test and as an anxiolytic 
compound on the time spent by STOP KO mice in the light/dark box. It had no effect on all 
other parameters and tests. The administered dose and the duration of the chronic treatment 
by epothilone D were selected according to previous study (Andrieux et al. 2006) and to 
Andrieux and Schweitzer (personal communication). Indeed, after 8-weeks treatment of 
STOP KO mice, 0.3-3 mg/kg/week epothilone D has been shown to be efficacious on some 
deficits and ineffective on others (Andrieux et al. 2006). 
Nevertheless, the absence of notable effects of chronic epothilone D treatment on the 
mood of WT and STOP KO mice suggests that administration of this microtubule-stabilizing 
drug in adult mice could not have a direct impact on the 5-HT and the NE 
neurotransmissions and/or the HPA axis. 
 
Both epothilone D and fluoxetine improved short-term memory of STOP KO mice 
Very interestingly, we showed that chronic epothilone D- and fluoxetine-treatments improved 
the short-term memory of STOP KO mice in the novel object recognition task. We previously 
Page 18 of 50Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
showed that STOP KO mice exhibit preserved very short-term memory in the spontaneous 
alternation test, but impaired short- and long-term memories in the novel object recognition 
task, as well as learning and memory in the Morris watermaze test  (Bouvrais-Veret et al. 
2007, Fournet et al. 2012). In the present work, control-treated STOP KO mice did not 
distinguish between the familiar and the novel objects after a time interval of 10 min, as in 
basal conditions. Very interestingly, they were able to preferentially explore novel objects 
after chronic epothilone D- and fluoxetine-treatments.  
Up to date, the only reports of a beneficial role of epothilone D or B on spatial learning 
and memory are on mouse models of tauopathy (Brunden et al. 2010, Barten et al. 2012, 
Zhang et al. 2012). In these studies, the cognitive improvement of the taxol-derivatives is 
associated with increased microtubule density, axonal integrity and decreased microtubule 
hyperdynamic. Such a relation between microtubule-targeting drugs and cognitive function is 
also found with the octapeptide NAP, a neuronal tubulin-preferring agent, in a mouse model 
of Alzheimer’s disease (Matsuoka et al. 2008), or in heterozygous STOP mice (Merenlender-
Wagner et al. 2010). In ou  case, the improvement of short-term memory of STOP KO mice 
by chronic epothilone D could be due to its beneficial effects on hippocampal synaptic 
number deficit, on post-tetanic and long-term potentiation defects and on their disorganized 
spontaneous activity (Andrieux et al. 2006).  
Various neuropsychiatric disorders, including mood disorders, elicited impaired 
memory and cognitive functions (Levkovitz et al. 2002, Gallassi et al. 2006, Mostert et al. 
2008). Thus, the effect of antidepressant therapy has been currently studied on a large scale 
of cognitive deficits, both in animal models and in human patients. Various studies reported 
the efficiency of chronic fluoxetine treatment on memory and learning deficits in several 
experimental mouse models: in two depressed models (learned helplessness and chronic 
mild stress, Song et al. 2006), in mice with ischemic stroke in hippocampus (Li et al. 2009) 
and in transgenic mice modeling the Down syndrome (Bianchi et al. 2010). Interestingly, the 
latter authors showed that chronic fluoxetine treatment could decrease acetylated alpha-
tubulin, indicating increased microtubule dynamics in rat hippocampus (Bianchi et al. 2009). 
Finally, fluoxetine therapy has positive effects regarding the cognitive impairments of 
depressed patients (Austin et al. 2001, Porter et al. 2003, Weiland-Fiedler et al. 2004, 
Gallassi et al. 2006), Alzheimer patients (Mowla et al. 2007) or after traumatic brain injury 
(Horsfield et al. 2002). 
 
Chronic treatments had no effect on SERT and NET densities 
The various effects of chronic epothilone D and fluoxetine treatments were not associated 
with consequences on the density of SERT and NET, following a 7-days washout. However, 
we have not measured their uptake activity. Due to the delayed onset of clinical efficacy of 
antidepressant therapy in mood disorders, the adaptive processes in 5-HT 
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neurotransmission to such treatments have been extensively studied. However, most works 
have focused on 5-HT receptor sensitivity. The consequences of prolonged antidepressant 
treatments on the SERT density are often controversial. For example, chronic administration 
of 2-10 mg/kg/day fluoxetine during 21 days induces either increase, or decrease, or has no 
effect on SERT brain density (Pineyro & Blier 1999, Benmansour et al. 2002, Hirano et al. 
2005). Taken together, these data indicate that adaptive responses of SERT to chronic 
fluoxetine treatment are not correlated with antidepressant effects. 
Interestingly, we found that the % variations of SERT and NET in both basal 
conditions and after control-treatment were highly correlated in various brain areas of STOP 
KO mice. However, the slope of the linear regression in the case of SERT was significantly 
higher from 1, suggesting that the chronic mild stress induced by the control-treatment 
exacerbated the 5-HT imbalance of STOP KO mice, whereas it was without consequence on 
the NE tone.  
 
Conclusion 
Stress and antidepressant actions are highly related. Accordingly, mice devoid of the STOP 
protein, which are pertinent for some schizoaffective-like symptoms, can constitute an 
original model to study such inter-relations between microtubular network, stress and mood 
disorders. They can be also useful to test innovative therapeutics, as those associating 
antipsychotic or antidepressant drugs with microtubule-stabilizing taxol analogs to alleviate 
some symptoms resistant to current therapy. 
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Legends to figures 
 
Fig. 1. Effects of chronic epothilone D and fluoxetine treatments on the depression-like 
status. A: Coat state. Data represent the means ± SEM of scores of 10 WT and STOP KO 
males treated by vehicule (C), epothilone D (E) from day 1 and fluoxetine (F) from day 7. B: 
Splash test. Means ± SEM of the latency time before the first grooming and of the grooming 
duration for 10 control-, epothilone D- and fluoxetine-treated WT and 10 control-, 9 
epothilone D- and 10 fluoxetine-treated STOP KO males. C: Forced swimming test. Means ± 
SEM of latency to immobilize, immobility duration and climbing attempts for 10 control-, 
epothilone D- and fluoxetine-treated WT and 9 control-, 9 epothilone D- and 10 fluoxetine-
treated STOP KO males. Post hoc Fisher’s test: * p < 0.050, ** p < 0.010, *** p < 0.001, 
comparison between genotypes; # p < 0.050, ## p < 0.010, ### p < 0.001, comparison 
between treatments; $$$ p < 0.001, effect of time. 
 
Fig. 2. Effects of chronic epothilone D and fluoxetine treatments on the anxiety-like status. A: 
Marble burying test. Means ± SEM of the number of marbles buried by 10 control-, 
epothilone D- and fluoxetine-treated WT and STOP KO males. B: Light/dark box test. Means 
± SEM of latency before the first visit, the time spent and of the visit number in the light box 
of 10 control-, epothilone D- and fluoxetine-treated WT and STOP KO males. Post hoc 
Fisher’s test: *** p < 0.001, comparison between genotypes; # p < 0.050, ## p < 0.010, ### p 
< 0.001, comparison between treatments. 
 
Fig. 3. Effects of chronic epothilone D and fluoxetine treatments on the memory 
performances. A: Spontaneous alternation test. Means ± SEM of the total number of visits in 
the three arms of the Y-maze and on the % spontaneous alternation of 10 control-, 10 
epothilone D- and 9 fluoxetine-treated WT and 10 control-, epothilone D- and fluoxetine-
treated STOP KO males. B: Novel object recognition task. Means ± SEM of the total time 
spent to explore the four objects in the sample-test and of the % time to explore the novel 
objects in the choice-test by 9 control-, 10 epothilone D- and 9 fluoxetine-treated WT and by 
10 control-,10 epothilone D- and 9 fluoxetine-treated STOP KO males. Post hoc Fisher’s test: 
* p < 0.050, ** p < 0.010, *** p < 0.001, comparison between genotypes; $ p = 0.054, ## p < 
0.010, comparison between treatments. Student’s t test: ‡ p < 0.050, ‡‡ p < 0.010, ‡‡‡ p < 
0.001, comparison between the novel (N) and familiar (F) objects. 
 
Fig. 4. Effects of acute stress on the depression- and anxiety-like status. In all tests, naïve 
male mice received an intraperitoneal administration of saline (Sal) or not (Bas), 30 min 
before testing. A: Forced swimming test. Means ± SEM of latency before the first immobility 
episode, immobility time and climbing attempts of 11 basal and 10 saline-treated WT and of 
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12 basal and 9 saline-treated STOP KO males. B: Tail suspension test. Means ± SEM of 
immobility time of 12 basal and saline-treated WT and of 12 basal and 10 saline-treated 
STOP KO males. C: Light/Dark box test. Means ± SEM of latency before the first visit, the 
time spent and the number of visits in the light box by 11 basal and saline-treated WT and 11 
basal and 9 saline-treated STOP KO males. Post hoc Fisher’s test: * p < 0.050, ** p < 0.010, 
*** p < 0.001, comparison between genotypes; # p < 0.050, ### p < 0.001, comparison 
between treatments. 
 
Fig. 5. Effect of stress on corticosterone, SERT and NET levels. A: Naïve WT and STOP KO 
males received an intraperitoneal administration of saline (Sal) or not (Bas), 30 min before 
sacrifice. Left: means ± SEM of plasma corticosterone levels in 6 mice per genotype and 
treatment. Right: means ± SEM of the stress-induced corticosterone increase, expressed as 
% of respective basal values. Post hoc Fisher’s test: *** p < 0.001, comparison between 
genotypes; ### p < 0.001, comparison between treatments. B: Correlation of SERT and NET 
density in various areas of STOP KO mice, in basal condition (Fournet et al. 2012) and after 
chronic stress (control-treatment). 
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Table 1 
Compared effects of acute stress, chronic stress and chronic fluoxetine on the mood status 
of WT and STOP KO males  
Test Parameter Acute stress Chronic stress Chronic fluoxetine a 
    WT KO WT KO WT KO 
Depression-status 
Coat State Score 58d      
+ 
depress 
  
- 
depress 
 
- 
depress  
                
Splash test Latency       
- 
depress 
  
- 
depress 
Grooming         
- 
depress 
  
Forced 
Swimming 
Test 
Latency   
- 
depress 
   
+ 
depress 
 
Immobility   
- 
depress 
 
- 
depress 
 
- 
depress 
  
+ 
depress 
Climbing   
- 
depress 
 
+ 
depress 
 
- 
depress 
  
  
Tail Suspen 
–sion Test 
Immobility   
- 
depress 
        
Anxiety-status 
Marble  
burying 
Number 
20’ 
     
- 
anxious 
  
- 
anxious 
 
- 
anxious 
                
Light/dark 
box 
Latency   
+ 
anxious 
   
+ 
anxious 
 
+ 
anxious 
Time L   
+ 
anxious 
  
+ 
anxious 
 
+ 
anxious 
 
+ 
anxious 
Number L   
+ 
anxious 
  
+ 
anxious 
 
+ 
anxious 
 
+ 
anxious 
Summary of the effects of acute (acute saline administration) and chronic stress (chronic 
vehicle-treatment) and of chronic fluoxetine treatment on the mood-status of WT and STOP 
KO male, as compared with basal conditions (Fournet et al. 2012, see Table S5). , no 
effect; , increase; , decrease. Status of STOP KO versus WT mice: +, more; –, less; 
depress, depressed; grey bottom: improvement (antidepressant or anxiolytic), black bottom: 
aggravation (prodepressant or anxiogenic). a, the effects of chronic fluoxetine were 
compared with chronic stress; L, light box. 
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The microtubule-associated STOP protein deletion triggers altered mood and 
cognitive performance in mice. Chronic treatments by epothilone D and fluoxetine of 
STOP KO mice increase their short-term memory. Moreover, STOP KO mice are 
hypersensitive to acute and chronic stress. These mice represent a valid model to 
study relationship between cytoskeleton, mood disorders and stress and to test 
innovative therapeutics. 
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SUPPLEMENTARY DATA 
 
Methods 
Forced Swimming Test 
The forced swimming test, adapted from Porsolt et al. (1979), was performed in a vertical 
glass cylinder (h= 30 cm; d= 15 cm) containing 20 cm of water maintained at 24 ± 1°C, under 
15 lux illumination. Latency before the first episode of immobility, the total duration of 
immobility and the number of climbing attempts were recorded for 6 min. An animal was 
judged to be immobile when it remained floating passively, performing slow motion to keep 
its head above the water. Climbing attempts were defined by upward-directed movements of 
the forepaws along the side of the container.  
 
Marble Burying Test 
The procedure for the marble burying test was adapted with minor modifications from Millan 
et al. (2001). Mice were individually placed in transparent cages containing a 4 cm layer of 
sawdust and 12 identical glass marbles (d = 1.6 cm) evenly spaced throughout the cage (4 
rows of 3 marbles), under a 50 lux illumination. The number of marbles buried by each 
mouse for more than two-thirds into the sawdust was scored every minute for 10 min and 
then every 5 min up to 20 min. 
 
Spontaneous Alternation 
This test was conducted, as already reported (Fournet et al. 2012), under 5 lux illumination in 
a Y-maze consisting of 3 identical and symmetrical arms (15 x 5 x 15 cm). Each mouse was 
introduced at the extremity of the same arm towards the center of the maze and was allowed 
to explore the apparatus freely over a 5 min period. The number of entries in arms (with four 
paws) and the sequence of visits into the 3 arms were recorded. A spontaneous alternation 
was defined as entries into all 3 arms on 3 consecutive choices (e.g. 1,2,3 or 1,3,2). The % 
of alternation of each mouse was expressed as the number of spontaneous alternation 
divided by the total number of entries minus 2.  
 
Novel Object Recognition Task 
This test was conducted as previously reported (Fournet et al. 2012) in a 50 lux illuminated 
arena (40 x 50 x 40 cm), with objects that could not be displaced by the mice. Prior to the 
test day, mice were habituated during 8 min for 2 successive days to the arena without 
objects and then for one day in the presence of 4 identical objects located in the corners of 
the area (4 cm from the wall). On the test day, each mouse was placed in the center of the 
arena for 8 min in the presence of four identical new objects (different from those of the 
habituation session) and the time spent exploring objects was recorded (sample phase). 
Mice were then removed and allowed to stay in their holding cage. After 10 min, animals 
returned to the arena for 8 min, with two objects from the sample phase (familiar objects) and 
two novel identical objects (choice phase). Between the sample and choice phases and 
between subjects, objects were cleaned to remove odor cues. Exploration was defined as 
mice directing their nose towards the object at a distance of less than 1 cm. Sitting close to 
or on top of the object was not considered as exploration. The relative duration the mice 
explored the novel objects was calculated as the ratio of the time spent to explore the novel 
objects over the total time spent exploring familiar and novel objects.  
 
Autoradiographic labelings of SERT and NET  
Seven days after the end of chronic treatments, mice were killed by cervical 
dislocation and their brain frozen in isopentane at –30°C. Serial 10 µm coronal sections were 
cut at –20°C, thaw-mounted on Superfrost Plus slides and stored at -80 °C until use. 
Sections were first pre-incubated before addition of radioactive ligands to rule out possible 
binding of 5-HT, NE, or fluoxetine to transporters. 
Labeling of the 5-HT transporter (SERT) was performed according to Fournet et al. 
(2010, 2012), by incubating slides for 60 min at room temperature in 50 mM Tris-HCl buffer, 
pH 7.4, containing 120 mM NaCl, 5 mM KCl and 2.5 nM [3H]citalopram (2.6-3.2 TBq/mmol), 
with or without 10 µM fluoxetine to determine non-specific binding. Sections were then 
washed in ice-cold buffer, rapidly rinsed in ice-cold water, dried and exposed to BAS-TR Fuji 
Imaging screen for 1-2 weeks.  
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Labeling of the NE transporter (NET) was performed according to Ordway et al. 
(1997), by incubating slides for 4 h at 4°C in 50 mM Tris-HCl buffer, pH 7.4, containing 300 
mM NaCl, 5 mM KCl and 2.5 nM [3H]nisoxetine (2.6-3.2 TBq/mmol), with or without 10 µM 
desipramine to determine non-specific binding. Sections were then washed in ice-cold buffer, 
rapidly rinsed in ice-cold water, dried and exposed to BAS-TR Fuji Imaging screen for 2-3 
weeks.  
Standard radioactive microscales were exposed onto each Imaging screen or film to 
ensure that labeling densities were in the linear range. The screens were scanned with a Fuji 
Bioimaging Analyzer BAS-5000 and the films numerized. Densitometry measurements were 
performed with MCIDTM analysis software. Specific labelings of 4-6 sections per area were 
averaged per mouse. 
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Results and Discussion 
 
Chronic epothilone D and fluoxetine treatments (Fig. S1A) 
The dose (1 mg/kg, once the week) and the duration (at least five weeks) of epothilone D 
treatment were chosen according to what was previously reported (Andrieux et al. 2002, 
Andrieux and Schweitzer, personal communication). The dose of fluoxetine (10 mg/kg/day) 
was chosen according to its acute inhibition of immobility of STOP KO mice in the tail 
suspension test (Fournet et al. 2012) and the treatment duration (at least four weeks) 
according to the therapeutic delay reported in the literature (Frazer & Benmansour 2002). 
 
Effect of chronic treatments on the body weight (Fig. S1B) 
Statistical analyses of data showed significant effects of genotype, treatment and time on the 
body weight of treated-males (Table S1). 
 As already shown (Fournet et al. 2012), the body weight of STOP KO versus WT 
males was significantly smaller at the beginning of the treatments (-15%, p < 0.0001) and 
this decreased weight persisted all along the treatments (control : -13%, p < 0.0001; 
epothilone: -10%, p < 0.0001; fluoxetine: -15%, p = < 0.0001; repeated measures). Whereas 
epothilone D treatment had no effect on the weight of WT mice, it significantly increased the 
weight of STOP KO mice (+5%, p < 0.0001, repeated measures). Fluoxetine treatment 
induced a significant decrease in the body weight of mice of both genotypes (WT: -6%, p < 
0.0001; STOP KO: -9%, p < 0.0001, repeated measures). Finally, the body weight growth of 
mice during the 9-weeks treatments was not different among genotypes and treatments. 
 The weight loss induced by chronic fluoxetine corresponds to a well-known action of 
selective serotonin reuptake inhibitors, which promote hypophagia (Yen & Fuller 1992, 
Curzon et al. 1997, Oruc et al. 1997) . 
 
Fluid intake during chronic treatments (Fig. S2A) 
All along the chronic treatments by epothilone D or fluoxetine, the fluid consumption by 
treated mice of both genotypes was regularly measured. Statistical analyses showed 
significant effects of time and of genotype x time and treatment x time interactions (Table 
S1). 
 The mean fluid intake by control-treated STOP KO mice was significantly smaller 
compared to control-treated WT mice (-10%, p = 0.0417; repeated measures). Whereas 
epothilone D treatment significantly decreased the fluid consumption at day 9 (WT: -19%, p = 
0.0167; KO: -37%, p = 0.0002), it had no further effect. As early as two days after the 
beginning of the treatment, fluoxetine elicited a decreased fluid consumption (WT: -37%, p = 
0.0002; KO: -48%, p < 0.0001). But after a 63-day treatment, fluoxetine no longer elicited a 
hypodypsic effect on both WT and STOP KO mice. This tolerance of WT and STOP KO mice 
to the hypodypsic effect of fluoxetine could not be attributed to decreased fluoxetine intake, 
which was constant between days 27 and 63 (see below). 
The decrease of fluid intake induced by fluoxetine is also a well known effect of 5-HT 
reuptake inhibitors, probably associated with their effect on food intake (Silva & Brandao 
2000, Thompson et al. 2004). Furthermore, the tolerance of mice of both genotypes to the 
hypodypsic effect elicited by chronic fluoxetine could be related to tolerance to the 
hypophagic effect of chronic fluoxetine (McGuirk et al. 1992).   
 
Effect of chronic treatments on SERT and NET density (Tables S3-S4) 
Statistical analysis showed significant effects of genotype and area on the density of SERT 
and NET in various brain areas (Table S2). Importantly, treatment had no significant effect on 
SERT and NET densities of treated-WT and -STOP KO mice. 
 As already reported (Fournet et al. 2010,  2012), SERT density (Table S3) in control-
treated STOP KO versus WT mice was increased in the cell body areas containing 
noradrenergic (locus coeruleus: +45%), serotonergic (dorsal raphe intermediate: +39%, 
dorsal raphe: +43% and median nucleus raphe: +27%) and dopaminergic (substantia nigra: 
+35% and ventral tegmental area: +45%) somas. In contrast, SERT density was highly 
decreased in all projection areas (from -30% in medial septum to -90% in medial entorhinal 
cortex).  
In the same manner but at a lesser extent, NET density (Table S4), in control-treated 
STOP KO versus WT mice, was increased in the cell body areas containing serotonergic 
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(dorsal raphe intermediate: +17%, dorsal raphe: +32% and median nucleus raphe: +42%) 
and dopaminergic (ventral tegmental area: +21%) somas. In contrast, NET density was 
decreased in all projection areas (from -25% in medial septum to -70% in medial entorhinal 
cortex). Finally, NET density was not different in the locus coeruleus and substantia nigra of 
control-treated STOP KO versus WT mice, as in basal conditions (Fournet et al. 2012). 
Interestingly, treatments by epothilone D and fluoxetine did not modify SERT and NET 
densities in the cerebral areas of treated-WT and -STOP KO mice.  
 
Comparison of the acute and chronic stress effects in the depression- and anxiety-
status (Table S5) 
The performances of WT and STOP KO males in depressed- and anxiety-like tests were 
compared in basal conditions, after acute stress and chronic stress and after chronic 
fluoxetine (data for male mice from Fournet et al. 2012 and our present study).  
In the coat state, analyses of data showed significant effects of genotype and 
treatment;  in the splash test, there were significant effects of genotype and treatment on 
latency and of genotype on the grooming duration; in the forced swimming test, analyses 
indicated a significant effect of genotype on latency, significant effects of genotype and 
treatment on the immobility time and the climbing attempts; in the tail suspension test, 
genotype and genotype x treatment interaction had significant effects on the immobility time 
(Table S2). 
Analyses of data indicated significant effects of genotype and treatment on the 
number of buried marbles and on latency, time spent and number of visits into the light box 
of the light/dark box test (Table S2). 
Page 37 of 50 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
References 
 
Andrieux, A., Salin, P. A., Vernet, M. et al. (2002) The suppression of brain cold-stable 
microtubules in mice induces synaptic defects associated with neuroleptic-sensitive 
behavioral disorders. Genes Dev, 16, 2350-2364. 
Curzon, G., Gibson, E. L. and Oluyomi, A. O. (1997) Appetite suppression by commonly 
used drugs depends on 5-HT receptors but not on 5-HT availability. Trends 
Pharmacol Sci, 18, 21-25. 
Fournet, V., Jany, M., Fabre, V. et al. (2010) The deletion of the microtubule-associated 
STOP protein affects the serotonergic mouse brain network. J Neurochem, 115, 
1579-1594. 
Fournet, V., Schweitzer, A., Chevarin, C., Deloulme, J. C., Hamon, M., Giros, B., Andrieux, 
A. and Martres, M. P. (2012) The deletion of STOP/MAP6 protein in mice triggers 
highly altered mood and impaired cognitive performances. J Neurochem, 121, 99-
114. 
Franklin, K. B. and Paxinos, G. (1997) The mouse brain in stereotaxic coordinates. Academic 
Press, Inc., San Diego, CA, USA. 
Frazer, A. and Benmansour, S. (2002) Delayed pharmacological effects of antidepressants. 
Mol Psychiatry, 7 Suppl 1, S23-28. 
McGuirk, J., Muscat, R. and Willner, P. (1992) Effects of chronically administered fluoxetine 
and fenfluramine on food intake, body weight and the behavioural satiety sequence. 
Psychopharmacology (Berl), 106, 401-407. 
Millan, M. J., Dekeyne, A., Papp, M., La Rochelle, C. D., MacSweeny, C., Peglion, J. L. and 
Brocco, M. (2001) S33005, a novel ligand at both serotonin and norepinephrine 
transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, 
citalopram, and clomipramine. J Pharmacol Exp Ther, 298, 581-591. 
Ordway, G. A., Stockmeier, C. A., Cason, G. W. and Klimek, V. (1997) Pharmacology and 
distribution of norepinephrine transporters in the human locus coeruleus and raphe 
nuclei. J Neurosci, 17, 1710-1719. 
Oruc, L., Verheyen, G., Furac, I., Jakovlejevic, M., Ivezic, S., Raeymaekers, P. and Van 
Broeckhoven, C. (1997) Association analysis of the 5-HT2C receptor and 5-HT 
transporter genes in bipolar disorder. Am J Medical Genetics (Neuropsychiatric 
Genetics), 74, 504-506. 
Porsolt, R. D., Bertin, A., Blavet, N., Deniel, M. and Jalfre, M. (1979) Immobility induced by 
forced swimming in rats: effects of agents which modify central catecholamine and 
serotonin activity. Eur J Pharmacol, 57, 201-210. 
Silva, R. C. and Brandao, M. L. (2000) Acute and chronic effects of gepirone and fluoxetine 
in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem 
Behav, 65, 209-216. 
Thompson, M. R., Li, K. M., Clemens, K. J., Gurtman, C. G., Hunt, G. E., Cornish, J. L. and 
McGregor, I. S. (2004) Chronic fluoxetine treatment partly attenuates the long-term 
anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. 
Neuropsychopharmacology, 29, 694-704. 
Yen, T. T. and Fuller, R. W. (1992) Preclinical pharmacology of fluoxetine, a serotonergic 
drug for weight loss. Am J Clin Nutr, 55, 177S-180S. 
 
 
Page 38 of 50Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
 
Legends to figures 
 
Fig. S1. A: Schema of chronic treatments and of the test sequence. B: Effects of chronic treatments 
on the body weight.  Means ± SEM of 10 males per genotype and per treatment. C, E and F: control-, 
epothilone D and fluoxetine chronic treatments, respectively. Post hoc Fisher’s test: * p < 0.050, *** p 
< 0.001, comparison between genotypes; ### p < 0.001, comparison between treatments (repeated 
measures); $$ p < 0.010, $$$ p < 0.001, comparison between times. 
 
Fig. S2. A: Total fluid consumption. Left: time course of total fluid consumption of 10 males per 
genotype and per treatment. Means ± SEM expressed in ml/10 g body weight/day. Right: comparison 
of the fluid consumption between day 9 and day 63. Means ±SEM. B: time course of fluoxetine 
consumption between day 9 and day 63. Means ± SEM in mg/kg/day for 10 males per genotype and 
per treatment. Dashed straights: mean fluoxetine consumption during the test period (day 41 to day 
63). Post hoc Fisher’s test: * p < 0.050,  ** p < 0.010, *** p < 0.001, comparison between genotypes; 
## p < 0.010, ### p < 0.001, comparison between treatments; $$$ p < 0.001, comparison between 
days of treatment. 
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Table S1 Statistical analyses 
Test Figure Parameter Factor degree F p 
Body weight Fig S1B Weight a time 7,42 12.30 <0.0001 
    genotype x time  7,42 2.18 0.0557 
    treatment x time 14,42 5.26 <0.0001 
Fluid intake Fig S2A Quantity a genotype 1,42 15.27 0.0079 
    treatment 2,42 5.41 0.0454 
    time 7,42 12.40 <0.0001 
    treatment x time  14,42 4.44 <0.0001 
Fluoxetine  Fig S2B Dose a genotype 1,144 4.20 0.0554 
intake   time  8,144 39.59 <0.0001 
   genotype x time 8,144 6.55 <0.0001 
  Dose 6-9 w a time 2,36 34.59 <0.0001 
Coat state Fig 1A Score a genotype 1,216 19.79 <0.0001 
    treatment 2,216 7.27 0.0016 
    time 4,126 3.91 0.0044 
    genotype x time  4,216 3.13 0.0156 
    treatment x time 8,216 3.99 0.0002 
Splash test Fig 1B Latency genotype 1,53 25.67 <0.0001 
   treatment 2,53 2.99 0.0586 
   Grooming genotype 1,53 15.27 0.0003 
   treatment 2,53 3.68 0.0319 
      genotype x treatment 2,53 3.83 0.0279 
Forced  Fig 1C Latency genotype 1,52 4.86 0.032 
swimming   treatment 2,52 6.24 0.0037 
test    genotype x treatment 2,52 3.65 0.0329 
  Immobility a genotype 1,104 6.80 0.0119 
   treatment 2,104 21.85 <0.0001 
   genotype x treatment 2,104 14.04 <0.0001 
    time 2,104 18.55 <0.0001 
    genotype x time 2,104 5.37 0.0061 
    g notype x treatment x time 4,104 3.37 0.0123 
  Climbing a genotype 1,104 10.68 0.0019 
   time 2,104 25.17 <0.0001 
Marble burying Fig 2A Number bur a genotype 1,594 4.44 0.0397 
    treatment 2,594 13.51 <0.0001 
    time 11,594 41.91 <0.0001 
    genotype x time  11,594 5.06 <0.0001 
    treatment x time 22,594 8.19 <0.0001 
Light/Dark box Fig 2B Latency treatment 2,54 7.06 0.0019 
  Time L treatment 2,54 15.27 <0.0001 
   Visit L genotype 1,54 6.49 0.0137 
    treatment 2,54 11.34 <0.0001 
Spontan Alter Fig 3A Tot Entries genotype 1,53 33.98 <0.0001 
Object  not shown Time: pre-test genotype 1,51 44.91 <0.0001 
recognition   treatment 2,51 4.53 0.0155 
task Fig 3B Time: test genotype 1,51 35.78 <0.0001 
    treatment 2,51 4.92 0.0111 
   %Time F, N object 1,102 84.69 < 0.0001 
   genotype x object 1,102 7.03 0.0093 
   treatment x object 2,102 7.75 0.0007 
SERT Table S3 Density genotype 1,529 8.12 0.0046 
   area  22,529 480.20 < 0.0001 
   genotype x area 22,529 21.69 < 0.0001 
NET Table S4 Density genotype 1,584 29.684 < 0.0001 
   area  22,584 405.88 < 0.0001 
   genotype x area 22,584 3.61 < 0.0001 
 
Only the significant ANOVA values are provided. a: repeated measures; bur: buried; F, N, familiar or 
novel object; L: light box; Spontan Alter: spontaneous alternation; Tot: total; w: week. 
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Table S2 Statistical analyses 
Test Figure Parameter Factor degree F p 
Acute stress versus basal 
Forced  Fig 4A Latency genotype 1,39 77.30 <0.0001 
swimming test  Immobility a stress 1,78 16.50 0.0002 
   genotype x stress 1,78 10.74 0.0022 
   time 2,78 20.78 <0.0001 
   genotype x time 2,78 13.78 <0.0001 
  Climbing a genotype 1,78 4.36 0.0434 
   stress 1,78 5.96 0.0193 
   genotype x stress 1,78 12.82 0.0009 
   time 2,78 30.57 <0.0001 
   genotype x time 2,78 21.60 <0.0001 
Tail suspension Fig 4B Immobility stress 1,42 11.21 0.0017 
 test     genotype x stress 1,42 14.93 0.0004 
Light/Dark box Fig 4D Latency genotype x stress 1,34 4.74 0.0365 
  Time L genotype 1,34 18.73 0.0001 
    stress 1,34 21.67 <0.0001 
    genotype x stress 1,34 6.25 0.0174 
   Visit L genotype 1,34 29.64 <0.0001 
    stress 1,34 17.73 0.0002 
      genotype x stress 1,34 10.53 0.0026 
Corticosterone Fig 5 Plasma level genotype 1,20 14.90 0.0010 
   stress 1,20 92.67 <0.0001 
   genotype x stress 1,20 5.70 0.0270 
  % Increase genotype 1,20 32.26 <0.0001 
   stress 1,20 127.12 <0.0001 
   genotype x stress 1,20 32.26 <0.0001 
Acute & chronic stress and fluoxetine versus basal 
Coat state Table S5 Score b genotype 1,65 21.01 <0.0001 
   treatment 2,65 18.27 <0.0001 
   genotype x treatment 2,65 5.23 0.0007 
Splash test Table S5 Latency genotype 1,62 30.74 <0.0001 
 Table S5  treatment 2,62 9.71 0.0002 
   genotype x treatment 2,62 5.44 0.0067 
  Grooming genotype 1,62 26.03 <0.0001 
   treatment 2,62 5.06 0.0092 
   genotype x treatment 2,62 5.28 0.0076 
Forced  Table S5 Latency genotype 1,74 50.55 <0.0001 
swimming test   treatment 3,74 8.60 <0.0001 
   genotype x treatment 3,74 2.99 0.0363 
  Immobility  treatment 3,74 25.31 <0.0001 
   genotype x treatment 3,74 9.80 <0.0001 
  Climbing  treatment 3,74 11.26 <0.0001 
   genotype x treatment 3,74 9.96 <0.0001 
Tail suspension Table S5 Immobility  treatment 1,42 11.21 0.0017 
 test   genotype x treatment 1,42 14.93 0.0004 
Marble burying Table S5 Number bur c genotype 1,65 33.86 <0.0001 
   treatment 2,65 34.77 <0.0001 
   genotype x treatment 2,65 10.33 <0.0001 
Light/Dark box Table S5 Latency genotype 1,68 4.42 0.0388 
   treatment  3,68 20.65 <0.0001 
   genotype x treatment 3,68 3.01 0.0361 
  Time L genotype 1,68 19.05 <0.0001 
   treatment  3,68 31.65 <0.0001 
   genotype x treatment 3,68 3.56 0.0186 
  Number L genotype 1,68 35.07 <0.0001 
   treatment 3,68 33.51 <0.0001 
   genotype x treatment 3,68 7.65 0.0002 
Only the significant ANOVA values are provided. a, repeated measures; b, score for the coat state 
at 58-day treatment; bur c, buried marbles at 20 min; L, light box. 
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Table S3 Statistical analyses 
 
Acute & chronic stress and fluoxetine versus basal 
Coat state Table 2 Score a genotype 1,65 21.01 <0.0001 
 Table S5  treatment 2,65 18.27 <0.0001 
   genotype x treatment 2,65 5.23 0.0007 
Splash test Table 2 Latency genotype 1,62 30.74 <0.0001 
 Table S5  treatment 2,62 9.71 0.0002 
   genotype x treatment 2,62 5.44 0.0067 
  Grooming genotype 1,62 26.03 <0.0001 
   treatment 2,62 5.06 0.0092 
   genotype x treatment 2,62 5.28 0.0076 
Forced  Table 2 Latency genotype 1,74 50.55 <0.0001 
swimming test Table S5  treatment 3,74 8.60 <0.0001 
   genotype x treatment 3,74 2.99 0.0363 
  Immobility  treatment 3,74 25.31 <0.0001 
   genotype x treatment 3,74 9.80 <0.0001 
  Climbing  treatment 3,74 11.26 <0.0001 
   genotype x treatment 3,74 9.96 <0.0001 
Tail suspension Table 2 Immobility  treatment 1,42 11.21 0.0017 
 test Table S5  genotype x treatment 1,42 14.93 0.0004 
Marble burying Table 2 Number bur b genotype 1,65 33.86 <0.0001 
 Table S5  treatment 2,65 34.77 <0.0001 
   genotype x treatment 2,65 10.33 <0.0001 
Light/Dark box Table 2 Latency genotype 1,68 4.42 0.0388 
 Table S5  treatment  3,68 20.65 <0.0001 
   genotype x treatment 3,68 3.01 0.0361 
  Time L genotype 1,68 19.05 <0.0001 
   treatment  3,68 31.65 <0.0001 
   genotype x treatment 3,68 3.56 0.0186 
  Number L genotype 1,68 35.07 <0.0001 
   treatment 3,68 33.51 <0.0001 
   genotype x treatment 3,68 7.65 0.0002 
 
Only the significant ANOVA values are provided. a, score for the coat state at 58-day 
treatment; bur b, buried marbles at 20 min; L, light box. 
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Table S3 Effects of chronic treatments on SERT densities in various areas of treated-mice 
 
Level Area WT KO 
  Epothilone Fluoxetine Control Epothilone Fluoxetine 
LC LC +8% ns +4% ns +47% *** +65% ns +63% ns 
 DRI +10% ns +15% ns +39% * +52% ns +57% ns 
       
Ra RS Cx 0% +4% ns -81% *** -85% ns  -82% ns 
 DR +6% ns +6% ns +43% *** +40% ns  +36% ns 
 MnR -2% ns +8% ns +27% *** +39% ns +45% ns 
 MEnt Cx -9% ns +1% ns -90% *** -91% ns -84% ns 
       
SN RS Cx -1% ns +8% ns -81% *** -81% ns -84% ns 
 Vis Cx -4% ns +13% ns -84% *** -87% ns -86% ns 
 Hipp -10% ns +3% ns -74% *** -73% ns -72% ns 
 SN -5% ns +13% ns  +35% *** +33% ns +34% ns 
 VTA -4% ns +12% ns +45% *** +50% ns +36% ns 
 MEnt Cx +5% ns -2% ns -80% *** -81% ns -75% ns 
       
Hipp RS Cx 0% +6% ns -73% *** -79% ns -73% ns 
 Mot Cx -5% ns +2% ns -78% *** -81% ns -77% ns 
 Sens Cx -6% ns +8% ns -80% *** -80% ns -78% ns 
 Hipp +2% ns +15% ns -41% *** -38% ns -38% ns 
 BLA -13% ns +5% ns -27% *** -22% ns -22% ns 
       
Str Cg Cx +2% ns +23% ns  -76% *** -75% ns -74% ns 
 Mot Cx -3% ns +15% ns -61% *** -58% ns -62% ns 
 Sens Cx -4% ns +16% ns -49% *** -43% ns -48% ns 
 CPu -4% ns +7% ns -50% *** -55% ns -48% ns 
 Acc 0% +14% ns -33% *** -45% ns -25% ns 
 mSept -3% ns +1% ns -30% *** -18% ns -33% ns 
 
Means ± SEM of SERT radiolabeling expressed as % of control-treated WT respective 
values for 4-5 mice per genotype and per treatment. Coronal levels: LC, locus coeruleus (IA 
= -1.72 to -1.54); Ra, raphe (IA = -0.80 to -0.40); SN, substantia nigra (IA = -0.08 to 0.88); 
Hipp, hippocampus (IA = 1.98 to 2.74); Str, striatum (IA = 4.78 to 5.34) according to Franklin 
& Paxinos (1997). See abbreviations in Table S6. Three-way ANOVA followed by Student’s t 
test: * p < 0.050; *** p < 0.001, comparison between genotypes; ns, not significant, 
comparison between treatments. 
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Table S4 Effects of chronic treatments on NET densities in various areas of treated-mice 
 
Level Area WT KO 
  Epothilone Fluoxetine Control Epothilone Fluoxetine 
LC LC -8% ns +6% ns -5% ns -2% ns -3% ns 
 DRI -11% ns +1% ns +17% *** +15% ns +22% ns 
       
Ra RS Cx +17% ns +21% ns -61% *** -64% ns -60% ns 
 DR -5% ns -4% ns +32 *** +26% ns +25% ns 
 MnR -15% ns -2% ns +42% *** +51% ns +56% ns 
 MEnt Cx -2% ns +5% ns -65% *** -63% ns -59% ns 
       
SN RS Cx +2% ns +22% ns -60% *** -69% ns -70% ns 
 Vis Cx -7% ns +13 % ns -64% *** -68% ns -70% ns 
 Hipp -21% ns +2% ns -57% *** -57% ns -64% ns 
 SN -18% ns +2% ns -2% ns -16% ns -3% ns 
 VTA -18% ns +2% ns +21% *** +8% ns +26% ns 
 MEnt Cx -6% ns -4% ns -67% *** -66% ns -67% ns 
       
Hipp RS Cx -2% ns 0% -49% *** -51% ns -56% ns 
 Mot Cx -4% ns -8% ns -57% *** -57% ns -62% ns 
 Sens Cx -5% ns -4% ns -57% *** -54% ns -59% ns 
 Hipp -2% ns -3% ns -47% *** -44% ns -50% ns 
 BLA +16% ns +2% ns -34% *** -32% ns -36% ns 
       
Str Cg Cx -5% ns -9% ns -50% *** -48% ns -53% ns 
 Mot Cx -1% ns -7% ns -36% *** -34% ns -44% ns 
 Sens Cx +5% ns +3% ns -33% *** -25% ns -42% ns 
 CPu -4% ns -2% ns -31% *** -41% ns -42% ns 
 Acc -13% ns -9% ns -28% *** -36% ns -37% ns 
 mSept -10% ns -10% ns -25% *** -33% ns -43% ns 
Means ± SEM of NET radiolabeling expressed as % of control-treated WT respective values 
for 4-5 mice per genotype and per treatment. Coronal levels: LC, locus coeruleus (IA = -1.72 
to -1.54); Ra, raphe (IA = -0.80 to -0.40); SN, substantia nigra (IA = -0.08 to 0.88); Hipp, 
hippocampus (IA = 1.98 to 2.74); Str, striatum (IA = 4.78 to 5.34) according to Franklin & 
Paxinos (1997). See abbreviations in Table S6. Three-way ANOVA followed by Student’s t 
test: ns non significant; *** p < 0.001, comparison between genotypes; ns, not significant, 
comparison between treatments. 
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Table S5 Performances of WT and STOP KO males after various treatments 
 
Parameter Basal Acute stress Chronic stress Chronic fluoxetine 
WT KO WT KO WT KO WT KO 
Coat state 
Score 58d 16.8±0.3 10.2±0.9*   8.3±1.9$ 8.4±1.4 19.6±0.2$# 12.4±2.0*# 
Splash test 
Latency 38.0±6.3 122±16*   29.4±4.5 71.7±13.3*$ 27.4±4.9 45.0±3.1*$ 
Grooming 137±8 74±14*   154±8 88±10* 140±10 136±6$# 
Forced swimming test 
Latency 56.0±6.1 8.0±2.4* 65.3±7.6 19.7±4.5*$ 72.5±17.3 21.3±8.4* 15.7±3.3$# 5.1±1.1* 
Immobility 188±10 241±12* 176±16 131±22$ 126±22$ 48±10*$ 169±15 238±20*# 
Climbing 53.4±5.7 12.8±1.8* 45.2±9.8 55.9±10.8$ 12.9±1.8$ 30.3±6.7*$ 17.0±3.8$ 17.7±4.6 
Tail suspension test 
Immobility 90±7 143±11* 96±17 58±10*$     
Marble burying test 
Number (a) 11.4±0.3 3.3±1.2*   6.4±0.8$ 3.2±0.7* 0.9±0.5$# 0±0$# 
Light/dark box test 
Latency 66.8±10.9 27.4±10.3* 55.9±8.1 59.6±9.1$ 35.1±11.2  47.4±7.6 207±38$# 122±26*$# 
Time L 48.8±6.0 96.1±9.1* 33.9±5.2  46.6±7.0$ 44.4±6.4 58.7±9.7$ 4.1±2.1$# 13.3±4.9$# 
Number L 5.6±0.7 13.4±1.4* 4.7±0.7  6.7±0.7$ 5.1±0.7 7.0 ±0.9$ 0.9±0.4$# 2.4±0.5*$# 
 
Means ± SEM of values for 9-17 WT and STOP KO males in basal condition (Fournet et al. 
2012 and this study), 9-12 WT and STOP KO males after acute stress, 9-10 WT and STOP 
KO males after chronic stress and fluoxetine treatment (mice of both genotypes in equal 
proportion for each test). (a) number at 20 min; L, light box. Two-way ANOVA followed by 
post hoc Fisher’s tests: * p < 0.05, comparison between genotypes; $ p < 0.05, comparison 
with basal conditions; # p < 0.05, comparison with chronic stress.  
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Table S6 Abbreviations 
 
 
Acc nucleus accumbens MnR median raphe nucleus 
BLA baso-lateral amygdala Mot Cx motor cortex 
Cg Cx cingulate cortex Ra raphe 
CPu caudate-putamen RS Cx retrosplenial cortex 
DR dorsal raphe nucleus Sens Cx somatosensory cortex 
DRI dorsal raphe intermediate SN substantia nigra 
Hipp hippocampus Str striatum 
LC locus coeruleus Vis Cx visual cortex 
mSept medial septum VTA ventral tegmental area 
MEnt Cx medial entorhinal cortex   
 
Abbreviations are from Franklin & Paxinos (1997). 
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